These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16392089)

  • 1. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
    Ribaudo HJ; Haas DW; Tierney C; Kim RB; Wilkinson GR; Gulick RM; Clifford DB; Marzolini C; Fletcher CV; Tashima KT; Kuritzkes DR; Acosta EP;
    Clin Infect Dis; 2006 Feb; 42(3):401-7. PubMed ID: 16392089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
    Haas DW; Gebretsadik T; Mayo G; Menon UN; Acosta EP; Shintani A; Floyd M; Stein CM; Wilkinson GR
    J Infect Dis; 2009 Mar; 199(6):872-80. PubMed ID: 19239339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
    Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
    Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
    Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.
    Leger P; Dillingham R; Beauharnais CA; Kashuba AD; Rezk NL; Fitzgerald DW; Pape JW; Haas DW
    J Infect Dis; 2009 Sep; 200(6):955-64. PubMed ID: 19659438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
    Wyen C; Hendra H; Siccardi M; Platten M; Jaeger H; Harrer T; Esser S; Bogner JR; Brockmeyer NH; Bieniek B; Rockstroh J; Hoffmann C; Stoehr A; Michalik C; Dlugay V; Jetter A; Knechten H; Klinker H; Skaletz-Rorowski A; Fätkenheuer G; Egan D; Back DJ; Owen A;
    J Antimicrob Chemother; 2011 Sep; 66(9):2092-8. PubMed ID: 21715435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz.
    Klein K; Lang T; Saussele T; Barbosa-Sicard E; Schunck WH; Eichelbaum M; Schwab M; Zanger UM
    Pharmacogenet Genomics; 2005 Dec; 15(12):861-73. PubMed ID: 16272958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
    Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Kumar P; Ramesh K; Anitha S; Narendran G; Menon P; Gomathi C; Swaminathan S
    Antimicrob Agents Chemother; 2009 Mar; 53(3):863-8. PubMed ID: 19124658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
    Lee KY; Lin SW; Sun HY; Kuo CH; Tsai MS; Wu BR; Tang SY; Liu WC; Chang SY; Hung CC
    PLoS One; 2014; 9(2):e88497. PubMed ID: 24551111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms.
    Lindfelt T; O'Brien J; Song JC; Patel R; Winslow DL
    Ann Pharmacother; 2010 Oct; 44(10):1572-8. PubMed ID: 20841522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.
    Cabrera SE; Santos D; Valverde MP; Domínguez-Gil A; González F; Luna G; García MJ
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2791-8. PubMed ID: 19433561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.
    Nyakutira C; Röshammar D; Chigutsa E; Chonzi P; Ashton M; Nhachi C; Masimirembwa C
    Eur J Clin Pharmacol; 2008 Apr; 64(4):357-65. PubMed ID: 18057928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms.
    Lee SS; To KW; Lee MP; Wong NS; Chan DP; Li PC; Cheung SW; Chan RC
    Int J STD AIDS; 2014 Mar; 25(3):193-200. PubMed ID: 23970651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
    Maimbo M; Kiyotani K; Mushiroda T; Masimirembwa C; Nakamura Y
    Eur J Clin Pharmacol; 2012 Mar; 68(3):267-71. PubMed ID: 21901344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
    Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
    Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
    Sukasem C; Cressey TR; Prapaithong P; Tawon Y; Pasomsub E; Srichunrusami C; Jantararoungtong T; Lallement M; Chantratita W
    Br J Clin Pharmacol; 2012 Dec; 74(6):1005-12. PubMed ID: 22471906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
    Holzinger ER; Grady B; Ritchie MD; Ribaudo HJ; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford DB; Daar ES; McLaren P; Haas DW
    Pharmacogenet Genomics; 2012 Dec; 22(12):858-67. PubMed ID: 23080225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese.
    To KW; Liu ST; Cheung SW; Chan DP; Chan RC; Lee SS
    Ther Drug Monit; 2009 Aug; 31(4):527-30. PubMed ID: 19531981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.
    Gandhi M; Greenblatt RM; Bacchetti P; Jin C; Huang Y; Anastos K; Cohen M; Dehovitz JA; Sharp GB; Gange SJ; Liu C; Hanson SC; Aouizerat B;
    J Infect Dis; 2012 Nov; 206(9):1453-61. PubMed ID: 22927450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.